Clinical trial
A 52-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
Name
CLI-06001AA1-04
Description
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
Trial arms
Trial start
2021-07-14
Estimated PCD
2025-06-13
Trial end
2025-06-20
Status
Recruiting
Phase
Early phase I
Treatment
Experimental: CHF6001 1600µg
CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
Arms:
CHF6001 1600µg
Experimental: CHF6001 3200µg
CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
Arms:
CHF6001 3200µg
Placebo
CHF6001 matching placebo, 2 inhalations bid.
Arms:
CHF6001 Placebo
Size
3435
Primary endpoint
The number of moderate and severe COPD exacerbations occurring during the planned 52-week treatment period.
Up to 52 weeks
Eligibility criteria
Inclusion Criteria:
* Adults aged ≥ 40 years with COPD and chronic bronchitis
* Current or ex-smokers (history ≥ 10 pack years).
* Post-bronchodilator FEV1 \<60% of the subject predicted normal value and FEV1/FVC ratio \< 0.7.
* At least, one moderate or severe COPD exacerbation in previous year.
* CAT score ≥ 10
* Subjects on regular maintenance triple therapy for at least 12 months prior to screening and receiving regular maintenance triple therapy for at least 3 months prior to screening visit
Exclusion Criteria:
* Subjects with current asthma.
* Subjects with moderate or severe COPD exacerbation 4 weeks prior to study entry and randomization.
* Subjects with known α-1 antitrypsin deficiency as the underlying cause of COPD.
* Subjects with COPD emphysema or mixed phenotypes.
* Subjects with known respiratory disorders other than COPD.
* Subjects with active cancer or a history of lung cancer with full recovery less than 1 year after completing cancer therapy.
* Subjects under Roflumilast treatment within 6 months before study entry.
* Subjects with a diagnosis of depression, generalised anxiety disorder, suicidal ideation.
* Subjects with clinically significant cardiovascular.
* Subjects with a significant neurological disease.
* Subjects with clinically significant laboratory abnormalities.
* Subjects with moderate or severe hepatic impairment
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 3435, 'type': 'ESTIMATED'}}
Updated at
2023-10-03
1 organization
2 products
1 indication
Organization
Chiesi FarmaceuticiProduct
CHF6001Indication
Chronic Obstructive Pulmonary DiseaseProduct
Placebo